Steidl Christian, Kridel Robert, Binkley Michael, Morton Lindsay M, Chadburn Amy
Centre for Lymphoid Cancer BC Cancer Vancouver British Columbia Canada.
Princess Margaret Cancer Centre - University Health Network Toronto Ontario Canada.
EJHaem. 2023 Sep 29;4(4):892-901. doi: 10.1002/jha2.785. eCollection 2023 Nov.
Lymphoid cancers are among the most frequent cancers diagnosed in adolescents and young adults (AYA), ranging from approximately 30%-35% of cancer diagnoses in adolescent patients (age 10-19) to approximately 10% in patients aged 30-39 years. Moreover, the specific distribution of lymphoid cancer types varies by age with substantial shifts in the subtype distributions between pediatric, AYA, adult, and older adult patients. Currently, biology studies specific to AYA lymphomas are rare and therefore insight into age-related pathogenesis is incomplete. This review focuses on the paradigmatic epidemiology and pathogenesis of select lymphomas, occurring in the AYA patient population. With the example of posttransplant lymphoproliferative disorders, nodular lymphocyte-predominant Hodgkin lymphoma, follicular lymphoma (incl. pediatric-type follicular lymphoma), and mediastinal lymphomas (incl. classic Hodgkin lymphoma, primary mediastinal large B cell lymphoma and mediastinal gray zone lymphoma), we here illustrate the current state-of-the-art in lymphoma classification, recent molecular insights including genomics, and translational opportunities. To improve outcome and quality of life, international collaboration in consortia dedicated to AYA lymphoma is needed to overcome challenges related to siloed biospecimens and data collections as well as to develop studies designed specifically for this unique population.
淋巴瘤是青少年和青年成人(AYA)中最常见的确诊癌症之一,在青少年患者(10 - 19岁)的癌症诊断中占比约30% - 35%,在30 - 39岁患者中占比约10%。此外,淋巴瘤类型的具体分布因年龄而异,在儿科、AYA、成人和老年成人患者之间的亚型分布有显著变化。目前,针对AYA淋巴瘤的生物学研究很少,因此对与年龄相关的发病机制的了解并不完整。本综述重点关注AYA患者群体中特定淋巴瘤的典型流行病学和发病机制。以移植后淋巴细胞增生性疾病、结节性淋巴细胞为主型霍奇金淋巴瘤、滤泡性淋巴瘤(包括儿童型滤泡性淋巴瘤)和纵隔淋巴瘤(包括经典霍奇金淋巴瘤、原发性纵隔大B细胞淋巴瘤和纵隔灰色地带淋巴瘤)为例,我们在此阐述淋巴瘤分类的当前最新进展、包括基因组学在内的近期分子见解以及转化机会。为了改善治疗效果和生活质量,需要致力于AYA淋巴瘤研究的国际合作联盟来克服与分散的生物标本和数据收集相关的挑战,并开展专门针对这一独特人群的研究。